Alnylam lung drug fails mid-stage trial

Alnylam lung drug fails mid-stage trial
(Reuters) – Alnylam Pharmaceuticals Inc&#39s experimental drug to treat a variety of respiratory infection in lung transplant patients missed the principal objective of a mid-stage trial. The drug, codenamed ALN-RSV01, is being developed to treat respiratory syncytial …
Read a lot more on Reuters

Relay for Life this weekend to salute &#39heroes&#39
The initial time was with Stage 1 breast cancer and the second with Stage three lung cancer. “I couldn&#39t get off the examining table the first time,” she mentioned. Because of her age, Miller-Webb had extensive therapy for the breast cancer.
Read far more on Bowling Green Daily News

CT Scans for Older Smokers Really should Lead to Earlier Lung Cancer Diagnoses
The objective of the CT scans is to detect lung cancer early enough so that treatment options can alter significantly the course of the disease. A benefit-risk analysis was based on evidence evaluation that included 53454 participants in 3 difference trials.
Read far more on